Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution
following transplantation of an autologous mobilized graft product to reconstitution
following transplantation of a mobilized graft product followed by an autologous lymphocyte
infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines
pre and post-transplant. The primary end point will be tetanus vaccine immune responses
post-transplant.